Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 7, 2013, Pages 1183-1191

  Okuda, Tomoyuki ^a   Kito, Daisuke ^a   Oiwa, Ai ^a   Fukushima, Michiko ^a   Hira, Daiki ^a   Okamoto, Hirokazu ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

Chitosan; Inhalable dry powder; Pulmonary gene delivery; Small interfering RNA; Supercritical fluid technique

Indexed keywords

CARBON DIOXIDE; CHITOSAN; MANNITOL; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISPERSION; DRUG DISTRIBUTION; DRUG SYNTHESIS; ELECTROPHORESIS; GENE SILENCING; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; UPREGULATION;

ANIMALS; CARBON DIOXIDE; CELL LINE, TUMOR; CHITOSAN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRY POWDER INHALERS; GENE SILENCING; LUCIFERASES, FIREFLY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; RNA, SMALL INTERFERING; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84880446740     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00167     Document Type: Article

References (44)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811 (1998).
2. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature, 457, 426-433 (2009).
3. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest., 117, 3623-3632 (2007).
4. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos., 34, 1393-1397 (2006).
5. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Löffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther., 13, 1222-1234 (2006).
6. Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-d- arabinonucleic acid (FANA). Nucleic Acids Res., 34, 1669-1675 (2006).
7. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol., 23, 457-462 (2005).
8. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, Lee PJ. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem., 279, 10677-10684 (2004).
9. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med., 11, 50-55 (2005).
10. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC, Zhong N, Lu PY. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med., 11, 944-951 (2005).
11. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MØ, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J. RNA interference in vitro and in vivo using a novel chitosan/ siRNA nanoparticle system. Mol. Ther., 14, 476-484 (2006).
12. Durcan N, Murphy C, Cryan SA. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol. Pharm., 5, 559-566 (2008).
13. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 56, 588-599 (2003).
14. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm. Res., 24, 411-437 (2007).
15. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release, 142, 138-145 (2010).
16. Yadava P, Gibbs M, Castro C, Hughes JA. Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS PharmSciTech, 9, 335-341 (2008).
17. Palakodaty S, York P, Pritchard J. Supercritical fluid processing of materials from aqueous solutions: the application of SEDS to lactose as a model substance. Pharm. Res., 15, 1835-1843 (1998).
18. Steckel H, Thies J, Muller BW. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int. J. Pharm., 152, 99-110 (1997).
19. Yeo SD, Lim GB, Debendetti PG, Bernstein H. Formation of microparticulate protein powder using a supercritical fluid antisolvent. Biotechnol. Bioeng., 41, 341-346 (1993).
20. Bodmeier R, Wang H, Dixon DJ, Mawson S, Johnston KP. Polymeric microspheres prepared by spraying into compressed carbon dioxide. Pharm. Res., 12, 1211-1217 (1995).
21. Frederiksen L, Anton K, van Hoogevest P, Keller HR, Leuenberger H. Preparation of liposomes encapsulating water-soluble compounds using supercritical carbon dioxide. J. Pharm. Sci., 86, 921-928 (1997).
22. Cape SP, Villa JA, Huang ET, Yang TH, Carpenter JF, Sievers RE. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm. Res., 25, 1967-1990 (2008).
23. Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res., 21, 1955-1969 (2004).
24. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv. Drug Deliv. Rev., 60, 433-446 (2008).
25. Tservistas M, Levy MS, Lo-Yim MY, O'Kennedy RD, York P, Humphrey GO, Hoare M. The formation of plasmid DNA loaded pharmaceutical powders using supercritical fluid technology. Biotechnol. Bioeng., 72, 12-18 (2001).
26. Okamoto H, Nishida S, Todo H, Sakakura Y, Iida K, Danjo K. Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process. J. Pharm. Sci., 92, 371-380 (2003).
27. Okamoto H, Sakakura Y, Shiraki K, Oka K, Nishida S, Todo H, Iida K, Danjo K. Stability of chitosan-pDNA complex powder prepared by supercritical carbon dioxide process. Int. J. Pharm., 290, 73-81 (2005).
28. Mizuno T, Mohri K, Nasu S, Danjo K, Okamoto H. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence. J. Control. Release, 134, 149-154 (2009).
29. Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon- β gene complex powder for inhalation treatment of lung metastasis in mice. J. Control. Release, 150, 187-195 (2011).
30. Fukuda Y, Tsuji T, Fujita T, Yamamoto A, Muranishi S. Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol. Pharm. Bull., 18, 891-894 (1995).
31. Todo H, Iida K, Okamoto H, Danjo K. Improvement of insulin absorption from intratracheally administrated dry powder prepared by supercritical carbon dioxide process. J. Pharm. Sci., 92, 2475-2486 (2003).
32. Strand SP, Tømmeraas K, Vårum KM, Østgaard K. Electrophoretic light scattering studies of chitosans with different degrees of Nacetylation. Biomacromolecules, 2, 1310-1314 (2001).
33. Kuo JH, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J. Pharm. Pharmacol., 56, 27-33 (2004).
34. Hahn LD, Kong H, Mooney DJ. Polycation structure mediates expression of lyophilized polycation/pDNA complexes. Macromol. Biosci., 10, 1210-1215 (2010).
35. Merkel OM, Beyerle A, Librizzi D, Pfestroff A, Behr TM, Sproat B, Barth PJ, Kissel T. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm., 6, 1246-1260 (2009).
36. Yamamoto A, Iseki T, Ochi-Sugiyama M, Okada N, Fujita T, Muranishi S. Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration site. J. Control. Release, 76, 363-374 (2001).
37. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med., 6, 100-102 (2000).
38. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev., 62, 12-27 (2010).
39. Huang M, Fong CW, Khor E, Lim LY. Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J. Control. Release, 106, 391-406 (2005).
40. Kiang T, Wen J, Lim HW, Leong KW. The effect of the degree of chitosan deacetylation on the efficiency of gene transfection. Biomaterials, 25, 5293-5301 (2004).
41. Liu X, Howard KA, Dong M, Andersen MØ, Rahbek UL, Johnsen MG, Hansen OC, Besenbacher F, Kjems J. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials, 28, 1280-1288 (2007).
42. Elouahabi A, Ruysschaert JM. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther., 11, 336-347 (2005).
43. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm., 392, 1-19 (2010).
44. Mohri K, Okuda T, Mori A, Danjo K, Okamoto H. Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation. J. Control. Release, 144, 221-226 (2010).